Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.
about
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell lymphoblastic leukemia.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@en
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@nl
type
label
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@en
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@nl
prefLabel
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@en
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of mTORC1/C2 signal ...... B-cell lymphoblastic leukemia.
@en
P2093
Antonio Cavazos
Charles G Mullighan
David A Fruman
David M Weinstock
Elias J Jabbour
Fenglin Cao
P2860
P304
P356
10.18632/ONCOTARGET.24261
P407
P577
2018-01-17T00:00:00Z